Comments on FDA plan to withdraw approval of all LABAs

Long acting beta-adrenoceptor agonists (LABAs) are usually prescribed for moderate to severe persistent asthma patients or patients with COPD.

See below some Twitter responses to the news that the FDA is planning to withdraw the approval of all LABAs. The updates are in a chronological order (oldest post at the top, newest post at the bottom of the page):

AllergyNotes FDA recommended withdrawing the approval of all LABAs? http://www.reuters.com/arti... 3:58 PM Dec 5th from web

wheezemd @AllergyNotes This could be a disaster in the treatment of asthma, especially for moderate to severe children. 5:03 PM Dec 5th from twitterrific in reply to AllergyNotes

AllergyNotes @wheezemd Banning LABAs "could be a disaster in the treatment of asthma, especially for moderate to severe children" -- Agree. 7:26 PM Dec 5th from web in reply to wheezemd

wheezemd FDA meets on LABAs this week. The question is can we prevent the FDA from banning LABAs in children. about 1 hour ago from web

wheezemd Many children with severe asthma respond to ICSs with LABAs. Do we go back to theophylline? Will we see more children hospitalized? about 1 hour ago from web

Follow new responses on Twitter Search.

References:

FDA sees asthma drug risks. Reuters.
The Lowdown on LABA's at Dr. Mintz' Blog
Image source: Fluticasone/salmeterol Diskus device, Wikipedia, public domain.

Related:

FDA Panel Considers Risks Of Asthma Drugs. NPR.
Update from Thorax 2012: Clearing the air: LABA/ICS reduce asthma hospitalizations, not associated with life-threatening events and deaths http://goo.gl/TesRp